close
Add to watchlist
Cardium Therapeutics Inc (CXM)
Cardium Therapeutics, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of therapeutic products and devices for cardiovascular, ischemic, and related indications. Its products include Generx, a DNA-based growth factor therapeutic that is in Phase III clinical stage designed to leverage the body's natural healing processes in response to repeated ischemic stress; Corgentin, a pre-clinical stage product, which enhances myocardial healing in and around the infarct zone when used as an adjunct to existing vascular-directed pharmacologic and interventional therapies; and Excellarate, a tissue repair's product candidate that is in Phase IIb clinical trial for the treatment of non-healing diabetic foot ulcers. The company also offers Celsius Control System to cool the body in order to reduce cell death and damage following acute ischemic events, such as cardiac arrest or stroke, and to lessen or prevent associated injuries, such as adverse neurological outcomes; RapidBlue endovascular system for endovascular temperature modulation; and CoolBlue surface temperature modulation system that provides a tool for use in less acute patients or in clinical settings suited to prolonged temperature management. In addition, Cardium Therapeutics is developing UroCoolTargeted Tissue Cooling System, a pelvic cooling catheter system designed to induce localized cooling during surgery for prostate cancer. It sells its products to medical teaching universities, hospitals, and private surgical centers throughout the United States. The company was founded in 2003 and is headquartered in San Diego, California.
(login to add this stock to your watchlist or favorites)
Key Statistics
| Closing Price | 0.28 |
| Volume | (mio) 1.15 |
| Volume Avg | 642413 |
| 52 Week High | 0.60 |
| 52 Week Low | 0.13 |
| PE | N/A |
| PE (group average) | N/A |
| EPS Year | -0.06 |
| EPS change Q/Q | -1000% |
| EPS change Q/Q Yr ago | -94.12% |
| EPS change Q/Q next Q est | -100% |
| EPS change Y/Y | -366.67% |
| REV change Q/Q | -100% |
| REV change Q/Q Yr ago | 0% |
| EPS next Q est | 0.00 |
| EPS next Y est | -0.07 |
| Divident Annual | 0.00 |
| Dividend Yield | 0% |